Abstracts Archive - Page 611 of 2425 - ACR Meeting Abstracts

Abstract Number: 1705 • ACR Convergence 2021
The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users
Marco Gianpiero Antivalle¹, Michele Agosti¹, Giuliana La Paglia², Alberto Batticciotto³, Maria Chiara Ditto⁴, SIMONE PARISI⁵ and Piercarlo Sarzi-Puttini⁶, ¹L. Sacco University Hospital, Milano, Italy, ²L.Sacco University Hospital, Milano, Lombardia, Italy, ³Ospedale di Circolo - Fondazione Macchi, Varese, Lombardia, Italy, ⁴AOU Città della Salute e della Scienza, Torino, Italy, ⁵AOU Città della Salute e della Scienza, TURIN, Italy, ⁶L.Sacco University Hospital, Milano, Italy
Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has…
Abstract Number: 1700 • ACR Convergence 2021
Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
Céleste van der Togt¹, Lise Verhoef², Nathan den Broeder³, Rob ter Heine³, Bart van den Bemt⁴ and Alfons den Broeder⁵, ¹Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ⁴Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁵Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…
Abstract Number: 1696 • ACR Convergence 2021
Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial
Maya Buch¹, Tsutomu Takeuchi², Vijay Rajendran³, Jacques-Eric Gottenberg⁴, Alena Pechonkina⁵, YingMeei Tan⁶, Qi Gong⁵, Katrien Van Beneden⁷ and Roberto Caporali⁸, ¹University of Leeds, Leeds, United Kingdom, ²Div. Rheumatology, Keio University, Tokyo, Japan, ³Galapagos NV, Mechelen, Belgium, ⁴National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Gilead Sciences, Inc, San Diego, CA, ⁷Galapagos, NV, Mechelen, Belgium, ⁸Policlinico S. Matteo University, Pavia, Italy
Background/Purpose: The preferential Janus kinase-1 inhibitor filgotinib (FIL) is approved to treat RA in Europe and Japan. We assessed FIL efficacy and safety in patients…
Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…
Abstract Number: 1712 • ACR Convergence 2021
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
Julianna Sabo¹, Namrata Singh², Deborah Crane¹, David Doody³, Melissa Schiff⁴ and Beth Mueller⁵, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴University of Washington, University of New Mexico, Seattle, WA, ⁵Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
Abstract Number: 1715 • ACR Convergence 2021
Providing High Quality Family Care Planning for Women with Rheumatic Disease in Rheumatology Clinics: Perspectives of Rheumatology Clinicians
Daiva Mitchell¹, Leslie Lesoon¹, Cuoghi Edens², Traci Kazmerski³, Olivia Stransky⁴, Megan Clowse⁵, Sonya Borrero⁴ and Mehret Birru Talabi⁴, ¹UPMC, Pittsburgh, PA, ²University of Chicago, Chicago, IL, ³Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Duke University, Chapel Hill, NC
Background/Purpose: While rheumatologists in several descriptive studies have acknowledged the importance of family planning in their care of women with rheumatic diseases, they have also…
Abstract Number: 1714 • ACR Convergence 2021
Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases
Olivia Stransky¹, Nicole Hunt², John Richards³ and Mehret Birru Talabi¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, PA, ³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA
Background/Purpose: Few studies have comprehensively evaluated the information needs and priorities that men with rheumatic diseases have about their sexual and reproductive health (SRH). This…
Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Jonah Gorodensky¹, Sasha Bernatsky¹, Waqqas Afif¹, Yvan St-Pierre², Kristian Filion¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…
Abstract Number: 1707 • ACR Convergence 2021
A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis
Yuqing Wang¹, Duolong Zhu¹, Laura Ortiz-Velez², Jacob Perry¹, Michael Pennington³, Joseph Hyser¹, Robert Britton¹ and Christine Beeton¹, ¹Baylor College of Medicine, Houston, TX, ²TMC Innovation, Houton, ³AmbioPharm Inc., North Augusta, SC
Background/Purpose: CCR7- effector memory T (TEM) lymphocytes are targets for immunomodulation for the treatment of rheumatoid arthritis (RA). Following activation, TEM cells upregulate the expression…
Abstract Number: 1718 • ACR Convergence 2021
Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide
Jun Chu¹, Alice Fike², Michael Davis³, Zerai Manna⁴, Komal Ejaz⁵, Yenealem Temesgen-Oyelakin⁶, Elaine Poncio⁷, Isabel Ochoa⁷, Alan Decherney⁴ and Sarfaraz Hasni⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³NIAMS, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Sheikh Zayed Medical College, Scranton, PA, ⁶National Institutes of Health (NIH), Bethesda, MD, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: SLE is an autoimmune disease which predominantly affects women of childbearing age (age 20-40). Most of the medications used for treating SLE can adversely…
Abstract Number: 1720 • ACR Convergence 2021
Cervical Dysplasia and HPV Infection in Women with Vasculitis
Taylor Koenig¹, Ambra Burrell², Hilary Kleppel³, Ashlee Weaver⁴, Veronica Mruk⁵, Lynn Fussner¹, Salem Almaani⁶ and Alexa Meara¹, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Division of Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Wright State University, Blacklick, OH, ⁴Ohio State University College of Medicine, Columbus, OH, ⁵Ohio State University / Nationwide Children's Hospital, Columbus, OH, ⁶Ohio State University Medical Center, Columbus, OH
Background/Purpose: The most common cause of cervical cancer is persistent human papillomavirus (HPV) infection in the cervical epithelium, causing precancerous cervical dysplasia and ultimately cervical…
Abstract Number: 1721 • ACR Convergence 2021
A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases
Lauren He, Rachel Karani, Gabriel Arenas and Cuoghi Edens, University of Chicago, Chicago, IL
Background/Purpose: Reproductive age women with rheumatic diseases are commonly cared for by non-rheumatologists who provide contraceptive counseling, preconception, pregnancy, and post-partum management. When women’s health…
Abstract Number: 1723 • ACR Convergence 2021
Factors Associated with Postpartum Flare in Women with Lupus
Anitha Ramu¹, Maedeh Veyseh¹, Brianna Lally², Shudan Wang³ and Anna Broder⁴, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁴Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Several prior studies have assessed disease activity in the setting of pregnancy and have shown that certain factors such as thrombocytopenia, systemic lupus erythematosus…
Abstract Number: 1717 • ACR Convergence 2021
One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center
Yixuan Zhou¹ and Sobia Hassan², ¹Rush University Medical Center, Chicago, IL, ²RUSH University, Chicago, IL
Background/Purpose: Successful pregnancies in patients with rheumatic disease are possible when they are well-monitored, adequately treated, and planned during periods of disease quiescence. Previously, a…
Abstract Number: 1697 • ACR Convergence 2021
Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial
Bernard Combe¹, Yoshiya Tanaka², Paul Emery³, Alena Pechonkina⁴, Albert Kuo⁴, Qi Gong⁴, Katrien Van Beneden⁵, Vijay Rajendran⁶ and Hendrik Schulze-Koops⁷, ¹CHU Montpellier Montpellier University, Montpellier, France, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos, NV, Mechelen, Belgium, ⁶Galapagos NV, Mechelen, Belgium, ⁷Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. We assessed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].